Cargando…
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
PURPOSE: To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). METHODS: A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932481/ https://www.ncbi.nlm.nih.gov/pubmed/29850205 http://dx.doi.org/10.1155/2018/4610129 |
_version_ | 1783319825471242240 |
---|---|
author | Best, Anne-Laurence Fajnkuchen, Franck Nghiem-Buffet, Sylvia Grenet, Typhaine Quentel, Gabriel Delahaye-Mazza, Corinne Cohen, Salomon Y. Giocanti-Aurégan, Audrey |
author_facet | Best, Anne-Laurence Fajnkuchen, Franck Nghiem-Buffet, Sylvia Grenet, Typhaine Quentel, Gabriel Delahaye-Mazza, Corinne Cohen, Salomon Y. Giocanti-Aurégan, Audrey |
author_sort | Best, Anne-Laurence |
collection | PubMed |
description | PURPOSE: To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). METHODS: A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. RESULTS: Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55). DISCUSSION/CONCLUSION: Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. |
format | Online Article Text |
id | pubmed-5932481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-59324812018-05-30 Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting Best, Anne-Laurence Fajnkuchen, Franck Nghiem-Buffet, Sylvia Grenet, Typhaine Quentel, Gabriel Delahaye-Mazza, Corinne Cohen, Salomon Y. Giocanti-Aurégan, Audrey J Ophthalmol Research Article PURPOSE: To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). METHODS: A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. RESULTS: Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55). DISCUSSION/CONCLUSION: Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. Hindawi 2018-04-18 /pmc/articles/PMC5932481/ /pubmed/29850205 http://dx.doi.org/10.1155/2018/4610129 Text en Copyright © 2018 Anne-Laurence Best et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Best, Anne-Laurence Fajnkuchen, Franck Nghiem-Buffet, Sylvia Grenet, Typhaine Quentel, Gabriel Delahaye-Mazza, Corinne Cohen, Salomon Y. Giocanti-Aurégan, Audrey Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
title | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
title_full | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
title_fullStr | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
title_full_unstemmed | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
title_short | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
title_sort | treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932481/ https://www.ncbi.nlm.nih.gov/pubmed/29850205 http://dx.doi.org/10.1155/2018/4610129 |
work_keys_str_mv | AT bestannelaurence treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT fajnkuchenfranck treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT nghiembuffetsylvia treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT grenettyphaine treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT quentelgabriel treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT delahayemazzacorinne treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT cohensalomony treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting AT giocantiaureganaudrey treatmentefficacyandcomplianceinpatientswithdiabeticmacularedematreatedwithranibizumabinareallifesetting |